4/8
04:16 pm
plrz
Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
Medium
Report
Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements
4/7
08:00 am
plrz
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
Medium
Report
Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement
3/28
01:05 am
plrz
Low
Report
3/26
09:23 am
plrz
Polyrizon Provides 2025 and Recent Highlights
Low
Report
Polyrizon Provides 2025 and Recent Highlights
3/25
05:36 pm
plrz
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 [TheStreet.com]
Medium
Report
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 [TheStreet.com]
3/25
05:25 pm
plrz
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Low
Report
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
3/24
08:47 am
plrz
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
Medium
Report
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications
3/17
08:25 am
plrz
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
Medium
Report
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program
3/10
07:55 am
plrz
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
Medium
Report
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study
2/26
08:12 am
plrz
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
Low
Report
Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product
2/17
11:32 am
plrz
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
Low
Report
Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker
2/10
06:55 am
plrz
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
Medium
Report
Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator
2/6
07:55 am
plrz
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
Low
Report
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
2/4
08:29 am
plrz
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company [Yahoo! Finance]
High
Report
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company [Yahoo! Finance]
2/4
07:12 am
plrz
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
High
Report
Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company
1/22
09:25 am
plrz
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker
Medium
Report
Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker